ClinicalTrials.gg
TerminatedNCT03617263Updated Dec 18, 2025Results posted

Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)

A Phase 2 interventional study of Saroglitazar Magnesium 4 mg Tablet and Placebo in Non-alcoholic Fatty Liver Disease in Women With PCOS, sponsored by Zydus Therapeutics Inc.. Terminated at 19 sites in 2 countries. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
217th of 460
60 · median 56
Started
2019
with 61 others
Phase 2
192 of 547
15 open now
Registered
251st of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 217th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 251st registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.

Read the detailed description

This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.

The study will be conducted over a period of up to 34 weeks and will include Screening (Days -28 to -7) Phase, a 24-week Treatment Phase following randomization on Day 1.

The primary endpoint of the study is change in hepatic fat content from baseline following 24 weeks of treatment as measured by MRI-PDFF.

03

Conditions studied

  • Non-alcoholic Fatty Liver Disease in Women With PCOS

Keywords

  • NAFLD
  • PCOS
  • Saroglitazar Magnesium
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females, 18 to 45 years of age.
  • Previously confirmed diagnosis of PCOS:

    1. oligo-and/or anovulation;
    2. hyperandrogenism (clinical and/or biochemical);
    3. polycystic ovary morphology on ultrasonography
  • Evidence of NAFLD within 6 months prior to the Screening Visit (Visit 1).
  • ≥ 38 U/L at Visit 1. Visit 2 ALT must not increase >30% from Visit 1.
  • Hepatic fat fraction ≥10% by MRI-PDFF.
  • Willingness to participate in the study.
  • Ability to understand and give for participation.
  • Woman who agrees to use the methods.

Exclusion criteria

Exclusion Criteria:

  • Presence of other chronic liver diseases ( or C, hepatitis, cholestatic liver disease, Wilsons disease, hemochromatosis, etc.).
  • Average alcohol consumption ≥ 7 drinks per week for women in the 6 months prior to enrollment.
  • Clinical, imaging, or histological evidence of cirrhosis.
  • Patients who have used medications known to cause hepatic steatosis for more than 2 weeks in the past year.
  • Prior bariatric surgery.
  • Weight loss of more than 5% in the 3 months preceding screening.
  • Severe co-morbidities (e.g., advanced cardiac, renal, pulmonary, or psychiatric illness).
  • Known allergy, sensitivity or intolerance to Saroglitazar Magnesium, comparator or formulation ingredients.
  • Use of antidiabetic and lipid lowering medications if the dose is not stable for at least the 3 months preceding screening.
  • Intake of Vitamin E (>100 IU/day) or multivitamins containing Vitamin E (>100 IU/day) 3 months before enrollment.
  • Use of drugs with potential effect on NAFLD/NASH in the 3 months prior to screening.
  • Illicit substance abuse within the past 12 months.
  • Pregnant or breast feeding females.
  • Women with known Cushing syndrome or hyperprolactinemia.
  • Refusal or inability to comply with the requirements of the protocol, for any reason, including scheduled clinic visits and laboratory tests.
  • History of myopathies or evidence of active muscle diseases.
  • History or current significant cardiovascular disease.
  • History of .
  • History of bladder disease.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Saroglitazar Magnesium 4 mg

    Saroglitazar Magnesium once daily in the morning before breakfast

    Drug: Saroglitazar Magnesium 4 mg Tablet

  • Placebo comparator
    Placebo

    Placebo tablet once daily in the morning before breakfast

    Drug: Placebo

Interventions

  • Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.

    Also known as: Not any

  • DrugPlacebo

    Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.

    Also known as: Not any

06

What researchers measure

Primary outcomes

  1. Hepatic Fat Content

    Change in hepatic fat content from baseline following 24 weeks of treatment as measured by Magnetic Resonance Imaging-derived Proton Density-fat Fraction (MRI-PDFF)

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Liver Enzymes/Liver Function Tests

    Changes from baseline to week 12 and week 24 in Alkaline phosphatase

    Time frame: Baseline, Week 12, and Week 24

  2. Liver Enzymes/Liver Function Tests

    Changes from baseline to week 12 and week 24 in Alanine aminotransferase

    Time frame: Baseline, Week 12, and Week 24

  3. Liver Enzymes/Liver Function Tests

    Changes from baseline to week 12 and week 24 in Aspartate Aminotransferase

    Time frame: Baseline, Week 12, and Week 24

  4. Liver Enzymes/Liver Function Tests

    Changes from baseline to week 12 and week 24 in gamma-glutamyl transferase

    Time frame: Baseline, Week 12, and Week 24

  5. Liver Enzymes/Liver Function Tests

    Changes from baseline to week 12 and week 24 in serum protein

    Time frame: Baseline, Week 12, and Week 24

  6. Liver Enzymes/Liver Function Tests

    Changes from baseline to week 12 and week 24 in albumin

    Time frame: Baseline, Week 12, and Week 24

  7. Liver Enzymes/Liver Function Tests

    Changes from baseline to week 12 and week 24 in total bilirubin.

    Time frame: Baseline, Week 12, and Week 24

  8. Insulin Resistance

    Evaluation of HOMA of Insulin Resistance Index determines insulin resistance and estimates insulin sensitivity, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance

    Time frame: Baseline, Week 12, and Week 24

  9. Liver Injury

    Changes from baseline to week 24 in Liver Injury, including Cytokeratin (CK)-18. CK18 \[M30\] and CK-18 \[M-65\] were measured as biomarkers of hepatocyte apoptosis. Both are important indicators for liver tissue conditions and effectively reflect hepatocyte damage. A negative change from baseline indicates a decrease in hepatocyte apoptosis or a decrease in hepatocyte damage.

    Time frame: Baseline and Week 24

  10. Liver Injury

    Changes from baseline to week 24 in high-sensitivity C-reactive protein (hs-CRP)

    Time frame: Baseline and Week 24

  11. Liver Injury

    Changes from baseline to week 24 in Tumor necrosis factor (TNFα)

    Time frame: Baseline and Week 24

  12. Liver Stiffness

    Changes from baseline to week 24 in liver stiffness measured by transient elastography/FibroScan

    Time frame: Baseline and Week 24

  13. Controlled Attenuation Parameter

    Changes from baseline to week 24 in controlled attenuation parameter measured by transient elastography/ FibroScan

    Time frame: Baseline and Week 24

  14. Body Mass Index (BMI)

    Changes from baseline to week 12 and week 24 in Body mass index

    Time frame: Baseline, Week 12, and Week 24

  15. Waist Circumference

    Changes from baseline to week 12 and week 24 in waist circumference

    Time frame: Baseline, Week 12, and Week 24

  16. Changes From Baseline to Week 24 in MRI-derived Measures of Total Liver Fat Index

    MRI-derived measures of total liver fat index. Total liver volume: The total liver volume was calculated through a process requiring segmentation image analysis. Liver volume was calculated after complete segmentation by summing the liver surface area at each segmented slice and then multiplying this sum by individual slice thickness, in milliliters (mL). Total liver fat index: The total liver fat index (TLFI, units: % mL) took into consideration the volume of liver from which proton-density fat fraction was derived. It was calculated as the product of liver volume and the liver mean proton-density fat fraction across all liver segments.

    Time frame: Baseline and Week 24

  17. Changes From Baseline to Week 24 in MRI-derived Measures of Total Liver Volume

    MRI-derived measures of total liver volume (Liver volume will be calculated after complete segmentation by summing the liver surface area at each segmented slice, and then multiplying this sum by individual slice thickness, in millilitres \[mL\])

    Time frame: Baseline and Week 24

  18. Lipid and Lipoprotein Levels

    Changes from baseline to week 12 and week 24 in Triglyceride (TG)

    Time frame: Baseline, Week 12, and Week 24

  19. Lipid and Lipoprotein Levels

    Changes from baseline to week 12 and week 24 in Total cholesterol (TC)

    Time frame: Baseline, Week 12, and Week 24

  20. Lipid and Lipoprotein Levels

    Changes from baseline to week 12 and week 24 in High-density lipoprotein

    Time frame: Baseline, Week 12, and Week 24

  21. Lipid and Lipoprotein Levels

    Changes from baseline to week 12 and week 24 in Low-density lipoprotein (LDL)

    Time frame: Baseline, Week 12, and Week 24

  22. Lipid and Lipoprotein Levels

    Changes from baseline to week 12 and week 24 in Small dense low density lipoprotein (sdLDL)

    Time frame: Baseline, Week 12, and Week 24

  23. Lipid and Lipoprotein Levels

    Changes from baseline to week 12 and week 24 in Very low density lipoprotein (VLDL)

    Time frame: Baseline, Week 12, and Week 24

  24. Lipid and Lipoprotein Levels

    Changes from baseline apolipoprotein A

    Time frame: Baseline, Week 12, and Week 24

  25. Lipid and Lipoprotein Levels

    Changes from baseline in apolipoprotein B

    Time frame: Baseline, Week 12, and Week 24

  26. Sex Hormone Binding Globulin (SHBG) Level

    Changes from baseline in SHBG level

    Time frame: Baseline, Week 12, and Week 24

  27. Ovarian Function

    Changes from baseline in 17-hydroxyprogesterone

    Time frame: Baseline, Week 12, and Week 24

  28. Ovarian Function

    Changes from baseline in Total testosterone

    Time frame: Baseline, Week 12, and Week 24

  29. Ovarian Function

    Changes from baseline in free testosterone

    Time frame: Baseline, Week 12, and Week 24

  30. Ovarian Function

    Changes from baseline in follicle-stimulating hormone (FSH)

    Time frame: Baseline, Week 12, and Week 24

  31. Ovarian Function

    Changes from baseline in luteinizing hormone (LH)

    Time frame: Baseline, Week 12, and Week 24

  32. Ovarian Function

    Changes from baseline in LH-to-FSH ratio

    Time frame: Baseline, Week 12, and Week 24

  33. Ovarian Function

    Changes from baseline in estradiol

    Time frame: Baseline, Week 12, and Week 24

  34. Changes From Baseline to Week 12 and Week 24 in Free Androgen Index

    Free androgen index is a ratio used to determine abnormal androgen status in humans, measured by Total testosterone level divided by the sex hormone binding globulin (SHBG) level, and then multiplying by a constant, usually 100. A higher score indicates a worse outcome (more androgenic).

    Time frame: Baseline, Week 12, and Week 24

  35. Peak Plasma Concentration [Cmax] (For Single Dose)

    Pharmacokinetics of Saroglitazar following first dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)

  36. Time to Reach Peak Plasma Concentration [Tmax] (For Single Dose)

    Pharmacokinetics of Saroglitazar following first dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)

  37. Area Under Plasma Concentration vs. Time Curve Till the Last Time Point [AUC0-t] (For Single Dose)

    Pharmacokinetics of Saroglitazar following first dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)

  38. Area Under Plasma Concentration vs. Time Curve Extrapolated to the Infinity (AUC0-∞) After First Dose (For Single Dose)

    Pharmacokinetics of Saroglitazar following first dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)

  39. Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval (AUCtau) After First Dose (For Single Dose)

    Pharmacokinetics of Saroglitazar following first dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)

  40. Elimination Rate Constant [Kel] (For Single Dose)

    Pharmacokinetics of Saroglitazar following first dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)

  41. Elimination Half-life [tHalf] (For Single Dose)

    Pharmacokinetics of Saroglitazar following first dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (Visit 3)

  42. Apparent Volume of Distribution [Vd/F] (For Single Dose)

    Pharmacokinetics of Saroglitazar following first dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)

  43. Apparent Clearance [CL/F] (For Single Dose)

    Pharmacokinetics of Saroglitazar following first dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)

  44. Peak Plasma Concentration [Cmax,ss] (For Multiple Dose)

    Pharmacokinetics of Saroglitazar following last dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0,10.0, and 24 hours post-dose of Last dose (Visit 8)

  45. Time to Reach Peak Plasma Concentration [Tmax,ss] (For Multiple Dose)

    Pharmacokinetics of Saroglitazar following last dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)

  46. Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval (AUCtau) After Last Dose (For Multiple Dose)

    Pharmacokinetics of Saroglitazar following last dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)

  47. Elimination Rate Constant [Kel,ss] (For Multiple Dose)

    Pharmacokinetics of Saroglitazar following last dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (Visit 8)

  48. Elimination Half-life [Thalf,ss] (For Multiple Dose)

    Pharmacokinetics of Saroglitazar following last dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)

  49. Apparent Volume of Distribution [Vd/F,ss] (For Multiple Dose)

    Pharmacokinetics of Saroglitazar following last dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)

  50. Apparent Clearance [CL/F,ss] (For Multiple Dose)

    Pharmacokinetics of Saroglitazar following last dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)

  51. Minimal or Trough Plasma Concentration [Cmin] (For Multiple Dose)

    Pharmacokinetics of Saroglitazar following last dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)

  52. Fluctuation Index (For Multiple Dose)

    Pharmacokinetics of Saroglitazar following the last dose. It is calculated as (Cmax - Cmin) / Cavg. The value has been multiplied by 100, hence has been expressed in percentage unit; where Cmax is the Maximum measured plasma concentration at steady state, Cmin is Minimal or trough plasma concentration at steady state, and Cavg is Average concentration = AUCtau,ss /tau.

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)

  53. Accumulation Index Calculated as a Ratio of AUCtau (Last Dose)/AUCtau (First Dose) (For Multiple Dose)

    Pharmacokinetics of Saroglitazar following last dose

    Time frame: PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)

07

Results

Posted Dec 18, 2025

Participant flow

Participant flow — Overall Study
MilestoneSaroglitazar Magnesium 4 mgPlacebo
Started3030
Completed2626
Not completed44

Outcome measures

PrimaryHepatic Fat Content

Change in hepatic fat content from baseline following 24 weeks of treatment as measured by Magnetic Resonance Imaging-derived Proton Density-fat Fraction (MRI-PDFF)

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · percentage of liver fat
Hepatic Fat Content
percentage of liver fatSaroglitazar Magnesium 4 mgPlacebo
Hepatic Fat Content-3.1741 ± 1.01800-0.3499 ± 1.06137
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0613
SecondaryLiver Enzymes/Liver Function Tests

Changes from baseline to week 12 and week 24 in Alkaline phosphatase

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · U/L
Liver Enzymes/Liver Function Tests
U/LSaroglitazar Magnesium 4 mgPlacebo
Week 12-22.64 ± 1.954-3.91 ± 2.083
Week 24-20.07 ± 2.520-1.66 ± 2.627
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = <.0001
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = <.0001
SecondaryLiver Enzymes/Liver Function Tests

Changes from baseline to week 12 and week 24 in Alanine aminotransferase

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · U/L
Liver Enzymes/Liver Function Tests
U/LSaroglitazar Magnesium 4 mgPlacebo
Week 12-22.00 ± 4.586-4.72 ± 4.894
Week 24-25.73 ± 4.276-8.30 ± 4.462
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0142
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0077
SecondaryLiver Enzymes/Liver Function Tests

Changes from baseline to week 12 and week 24 in Aspartate Aminotransferase

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · U/L
Liver Enzymes/Liver Function Tests
U/LSaroglitazar Magnesium 4 mgPlacebo
Week 12-9.97 ± 4.233-3.31 ± 4.514
Week 24-11.27 ± 4.437-2.88 ± 4.627
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.2893
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.1989
SecondaryLiver Enzymes/Liver Function Tests

Changes from baseline to week 12 and week 24 in gamma-glutamyl transferase

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · U/L
Liver Enzymes/Liver Function Tests
U/LSaroglitazar Magnesium 4 mgPlacebo
Week 12-22.62 ± 2.629-1.52 ± 2.807
Week 24-21.46 ± 2.545-2.37 ± 2.656
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = <.0001
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = <.0001
SecondaryLiver Enzymes/Liver Function Tests

Changes from baseline to week 12 and week 24 in serum protein

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · g/L
Liver Enzymes/Liver Function Tests
g/LSaroglitazar Magnesium 4 mgPlacebo
Week 120.01 ± 0.0720.02 ± 0.077
Week 24-0.14 ± 0.0710.03 ± 0.074
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.8664
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.1137
SecondaryLiver Enzymes/Liver Function Tests

Changes from baseline to week 12 and week 24 in albumin

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · g/L
Liver Enzymes/Liver Function Tests
g/LSaroglitazar Magnesium 4 mgPlacebo
Week 121.06 ± 0.477-0.39 ± 0.510
Week 240.06 ± 0.485-0.15 ± 0.507
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0487
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.7743
SecondaryLiver Enzymes/Liver Function Tests

Changes from baseline to week 12 and week 24 in total bilirubin.

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · mg/dL
Liver Enzymes/Liver Function Tests
mg/dLSaroglitazar Magnesium 4 mgPlacebo
Week 12-0.076 ± 0.0294-0.008 ± 0.0313
Week 24-0.066 ± 0.0290-0.004 ± 0.0302
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.1174
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.1483
SecondaryInsulin Resistance

Evaluation of HOMA of Insulin Resistance Index determines insulin resistance and estimates insulin sensitivity, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · Index
Insulin Resistance
IndexSaroglitazar Magnesium 4 mgPlacebo
Week 12-1.983 ± 1.21921.081 ± 1.3004
Week 240.498 ± 2.19104.303 ± 2.2852
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0941
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.2378
SecondaryLiver Injury

Changes from baseline to week 24 in Liver Injury, including Cytokeratin (CK)-18. CK18 \[M30\] and CK-18 \[M-65\] were measured as biomarkers of hepatocyte apoptosis. Both are important indicators for liver tissue conditions and effectively reflect hepatocyte damage. A negative change from baseline indicates a decrease in hepatocyte apoptosis or a decrease in hepatocyte damage.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · U/L
Liver Injury
U/LSaroglitazar Magnesium 4 mgPlacebo
M30-238.801 ± 69.9009-92.160 ± 72.8890
M65-260.232 ± 100.6148-72.273 ± 104.9207
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.1542
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.2037
SecondaryLiver Injury

Changes from baseline to week 24 in high-sensitivity C-reactive protein (hs-CRP)

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/L
Liver Injury
mg/LSaroglitazar Magnesium 4 mgPlacebo
Liver Injury-1.00 ± 1.3810.55 ± 1.440
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.4431
SecondaryLiver Injury

Changes from baseline to week 24 in Tumor necrosis factor (TNFα)

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · ng/L
Liver Injury
ng/LSaroglitazar Magnesium 4 mgPlacebo
Liver Injury0.109 ± 0.27110.587 ± 0.2827
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.2289
SecondaryLiver Stiffness

Changes from baseline to week 24 in liver stiffness measured by transient elastography/FibroScan

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · kPa
Liver Stiffness
kPaSaroglitazar Magnesium 4 mgPlacebo
Liver Stiffness-0.75 ± 0.9531.67 ± 0.994
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0853
SecondaryControlled Attenuation Parameter

Changes from baseline to week 24 in controlled attenuation parameter measured by transient elastography/ FibroScan

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · dB/m
Controlled Attenuation Parameter
dB/mSaroglitazar Magnesium 4 mgPlacebo
Controlled Attenuation Parameter-18.84 ± 9.119-3.40 ± 9.521
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.2559
SecondaryBody Mass Index (BMI)

Changes from baseline to week 12 and week 24 in Body mass index

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · kg/m^2
Body Mass Index (BMI)
kg/m^2Saroglitazar Magnesium 4 mgPlacebo
Week 120.101 ± 0.28170.272 ± 0.3003
Week 240.273 ± 0.3132-0.066 ± 0.3266
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.6800
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.4587
SecondaryWaist Circumference

Changes from baseline to week 12 and week 24 in waist circumference

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · cm
Waist Circumference
cmSaroglitazar Magnesium 4 mgPlacebo
Week 121.285 ± 0.98791.142 ± 1.0783
Week 241.607 ± 0.89191.127 ± 0.9300
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.9230
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.7115
SecondaryChanges From Baseline to Week 24 in MRI-derived Measures of Total Liver Fat Index

MRI-derived measures of total liver fat index. Total liver volume: The total liver volume was calculated through a process requiring segmentation image analysis. Liver volume was calculated after complete segmentation by summing the liver surface area at each segmented slice and then multiplying this sum by individual slice thickness, in milliliters (mL). Total liver fat index: The total liver fat index (TLFI, units: % mL) took into consideration the volume of liver from which proton-density fat fraction was derived. It was calculated as the product of liver volume and the liver mean proton-density fat fraction across all liver segments.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · %mL
Changes From Baseline to Week 24 in MRI-derived Measures of Total Liver Fat Index
%mLSaroglitazar Magnesium 4 mgPlacebo
Changes From Baseline to Week 24 in MRI-derived Measures of Total Liver Fat Index-78.493 ± 38.0001-8.963 ± 37.1636
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.1983
SecondaryChanges From Baseline to Week 24 in MRI-derived Measures of Total Liver Volume

MRI-derived measures of total liver volume (Liver volume will be calculated after complete segmentation by summing the liver surface area at each segmented slice, and then multiplying this sum by individual slice thickness, in millilitres \[mL\])

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mL
Changes From Baseline to Week 24 in MRI-derived Measures of Total Liver Volume
mLSaroglitazar Magnesium 4 mgPlacebo
Changes From Baseline to Week 24 in MRI-derived Measures of Total Liver Volume-66.886 ± 70.3776-36.176 ± 68.8178
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.7576
SecondaryLipid and Lipoprotein Levels

Changes from baseline to week 12 and week 24 in Triglyceride (TG)

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · mg/dL
Lipid and Lipoprotein Levels
mg/dLSaroglitazar Magnesium 4 mgPlacebo
Week 12-41.535 ± 12.3535-21.665 ± 13.1733
Week 24-47.886 ± 15.864214.724 ± 16.5423
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.2784
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0091
SecondaryLipid and Lipoprotein Levels

Changes from baseline to week 12 and week 24 in Total cholesterol (TC)

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · mg/dL
Lipid and Lipoprotein Levels
mg/dLSaroglitazar Magnesium 4 mgPlacebo
Week 12-16.807 ± 3.8832-6.992 ± 4.1447
Week 24-22.650 ± 3.7464-3.120 ± 3.9095
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0941
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0009
SecondaryLipid and Lipoprotein Levels

Changes from baseline to week 12 and week 24 in High-density lipoprotein

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · mg/dL
Lipid and Lipoprotein Levels
mg/dLSaroglitazar Magnesium 4 mgPlacebo
Week 122.327 ± 1.3110-0.599 ± 1.3986
Week 240.676 ± 1.4851-1.561 ± 1.5491
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.1363
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.3057
SecondaryLipid and Lipoprotein Levels

Changes from baseline to week 12 and week 24 in Low-density lipoprotein (LDL)

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · mg/dL
Lipid and Lipoprotein Levels
mg/dLSaroglitazar Magnesium 4 mgPlacebo
Week 12-10.318 ± 3.7934-4.821 ± 4.0492
Week 24-13.457 ± 3.0454-4.938 ± 3.1785
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.3323
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0624
SecondaryLipid and Lipoprotein Levels

Changes from baseline to week 12 and week 24 in Small dense low density lipoprotein (sdLDL)

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · mg/dL
Lipid and Lipoprotein Levels
mg/dLSaroglitazar Magnesium 4 mgPlacebo
Week 12-6.918 ± 2.0576-4.889 ± 2.1943
Week 24-9.000 ± 1.9510-2.574 ± 2.0346
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.5050
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0279
SecondaryLipid and Lipoprotein Levels

Changes from baseline to week 12 and week 24 in Very low density lipoprotein (VLDL)

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · mg/dL
Lipid and Lipoprotein Levels
mg/dLSaroglitazar Magnesium 4 mgPlacebo
Week 12-7.102 ± 2.5927-3.521 ± 2.7645
Week 24-8.736 ± 2.91683.452 ± 3.0413
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.3508
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0059
SecondaryLipid and Lipoprotein Levels

Changes from baseline apolipoprotein A

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · mg/dL
Lipid and Lipoprotein Levels
mg/dLSaroglitazar Magnesium 4 mgPlacebo
Week 124.486 ± 3.87602.130 ± 4.1326
Week 24-2.830 ± 3.1112-1.272 ± 3.2442
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.6800
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.7310
SecondaryLipid and Lipoprotein Levels

Changes from baseline in apolipoprotein B

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · mg/dL
Lipid and Lipoprotein Levels
mg/dLSaroglitazar Magnesium 4 mgPlacebo
Week 12-10.673 ± 2.7834-3.508 ± 2.9723
Week 24-13.146 ± 2.3060-3.233 ± 2.4071
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0896
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0053
SecondarySex Hormone Binding Globulin (SHBG) Level

Changes from baseline in SHBG level

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · nmol/L
Sex Hormone Binding Globulin (SHBG) Level
nmol/LSaroglitazar Magnesium 4 mgPlacebo
Week 1217.182 ± 13.149627.506 ± 14.0281
Week 24-3.882 ± 8.05218.286 ± 8.3982
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.5962
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.3035
SecondaryOvarian Function

Changes from baseline in 17-hydroxyprogesterone

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · ng/dL
Ovarian Function
ng/dLSaroglitazar Magnesium 4 mgPlacebo
Week 128.800 ± 9.7348-4.819 ± 10.3892
Week 24-10.325 ± 6.8372-2.168 ± 7.1337
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.3482
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.4176
SecondaryOvarian Function

Changes from baseline in Total testosterone

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · nmol/L
Ovarian Function
nmol/LSaroglitazar Magnesium 4 mgPlacebo
Week 12-0.173 ± 0.1134-0.171 ± 0.1209
Week 24-0.231 ± 0.1182-0.073 ± 0.1233
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.9930
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.3612
SecondaryOvarian Function

Changes from baseline in free testosterone

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · nmol/L
Ovarian Function
nmol/LSaroglitazar Magnesium 4 mgPlacebo
Week 12-0.005 ± 0.0028-0.009 ± 0.0030
Week 24-0.005 ± 0.0028-0.003 ± 0.0029
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.4373
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.6248
SecondaryOvarian Function

Changes from baseline in follicle-stimulating hormone (FSH)

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · IU/L
Ovarian Function
IU/LSaroglitazar Magnesium 4 mgPlacebo
Week 12-0.892 ± 0.3356-1.722 ± 0.3580
Week 24-0.689 ± 0.3196-1.125 ± 0.3334
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0994
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.3527
SecondaryOvarian Function

Changes from baseline in luteinizing hormone (LH)

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · IU/L
Ovarian Function
IU/LSaroglitazar Magnesium 4 mgPlacebo
Week 12-1.140 ± 0.8881-1.632 ± 0.9467
Week 24-1.305 ± 1.20200.140 ± 1.2532
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.7065
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.4096
SecondaryOvarian Function

Changes from baseline in LH-to-FSH ratio

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · Ratio
Ovarian Function
RatioSaroglitazar Magnesium 4 mgPlacebo
Week 12-0.230 ± 0.17310.064 ± 0.1808
Week 24-0.324 ± 0.22260.136 ± 0.2326
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.2475
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.1621
SecondaryOvarian Function

Changes from baseline in estradiol

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · pmol/L
Ovarian Function
pmol/LSaroglitazar Magnesium 4 mgPlacebo
Week 12-57.237 ± 41.4020-24.045 ± 44.1354
Week 24-105.380 ± 65.598317.209 ± 68.3930
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.5862
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.2026
SecondaryChanges From Baseline to Week 12 and Week 24 in Free Androgen Index

Free androgen index is a ratio used to determine abnormal androgen status in humans, measured by Total testosterone level divided by the sex hormone binding globulin (SHBG) level, and then multiplying by a constant, usually 100. A higher score indicates a worse outcome (more androgenic).

Time frame:
Baseline, Week 12, and Week 24
Reported as:
Least squares mean · Ratio
Changes From Baseline to Week 12 and Week 24 in Free Androgen Index
RatioSaroglitazar Magnesium 4 mgPlacebo
Week 12-0.371 ± 0.1637-0.483 ± 0.1746
Week 24-0.253 ± 0.1742-0.256 ± 0.1816
Statistical analysis
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.6434
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.9895
SecondaryPeak Plasma Concentration [Cmax] (For Single Dose)

Pharmacokinetics of Saroglitazar following first dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Reported as:
Mean · ng/mL
Peak Plasma Concentration [Cmax] (For Single Dose)
ng/mLSaroglitazar Magnesium 4 mg
Peak Plasma Concentration [Cmax] (For Single Dose)120.250 ± 49.997
SecondaryTime to Reach Peak Plasma Concentration [Tmax] (For Single Dose)

Pharmacokinetics of Saroglitazar following first dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Reported as:
Mean · hour
Time to Reach Peak Plasma Concentration [Tmax] (For Single Dose)
hourSaroglitazar Magnesium 4 mg
Time to Reach Peak Plasma Concentration [Tmax] (For Single Dose)1.902 ± 1.103
SecondaryArea Under Plasma Concentration vs. Time Curve Till the Last Time Point [AUC0-t] (For Single Dose)

Pharmacokinetics of Saroglitazar following first dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Reported as:
Mean · ng*hr/mL
Area Under Plasma Concentration vs. Time Curve Till the Last Time Point [AUC0-t] (For Single Dose)
ng*hr/mLSaroglitazar Magnesium 4 mg
Area Under Plasma Concentration vs. Time Curve Till the Last Time Point [AUC0-t] (For Single Dose)486.033 ± 188.320
SecondaryArea Under Plasma Concentration vs. Time Curve Extrapolated to the Infinity (AUC0-∞) After First Dose (For Single Dose)

Pharmacokinetics of Saroglitazar following first dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Reported as:
Mean · ng/mL*hr
Area Under Plasma Concentration vs. Time Curve Extrapolated to the Infinity (AUC0-∞) After First Dose (For Single Dose)
ng/mL*hrSaroglitazar Magnesium 4 mg
Area Under Plasma Concentration vs. Time Curve Extrapolated to the Infinity (AUC0-∞) After First Dose (For Single Dose)473.771 ± 182.430
SecondaryArea Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval (AUCtau) After First Dose (For Single Dose)

Pharmacokinetics of Saroglitazar following first dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Reported as:
Mean · ng*hr/mL
Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval (AUCtau) After First Dose (For Single Dose)
ng*hr/mLSaroglitazar Magnesium 4 mg
Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval (AUCtau) After First Dose (For Single Dose)491.981 ± 192.373
SecondaryElimination Rate Constant [Kel] (For Single Dose)

Pharmacokinetics of Saroglitazar following first dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Reported as:
Mean · 1/hr
Elimination Rate Constant [Kel] (For Single Dose)
1/hrSaroglitazar Magnesium 4 mg
Elimination Rate Constant [Kel] (For Single Dose)0.144 ± 0.057
SecondaryElimination Half-life [tHalf] (For Single Dose)

Pharmacokinetics of Saroglitazar following first dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (Visit 3)
Reported as:
Mean · hr
Elimination Half-life [tHalf] (For Single Dose)
hrSaroglitazar Magnesium 4 mg
Elimination Half-life [tHalf] (For Single Dose)5.317 ± 1.559
SecondaryApparent Volume of Distribution [Vd/F] (For Single Dose)

Pharmacokinetics of Saroglitazar following first dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Reported as:
Mean · L
Apparent Volume of Distribution [Vd/F] (For Single Dose)
LSaroglitazar Magnesium 4 mg
Apparent Volume of Distribution [Vd/F] (For Single Dose)77.890 ± 42.887
SecondaryApparent Clearance [CL/F] (For Single Dose)

Pharmacokinetics of Saroglitazar following first dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of First dose (visit 3)
Reported as:
Mean · L/hr
Apparent Clearance [CL/F] (For Single Dose)
L/hrSaroglitazar Magnesium 4 mg
Apparent Clearance [CL/F] (For Single Dose)9.305 ± 3.599
SecondaryPeak Plasma Concentration [Cmax,ss] (For Multiple Dose)

Pharmacokinetics of Saroglitazar following last dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0,10.0, and 24 hours post-dose of Last dose (Visit 8)
Reported as:
Mean · ng/mL
Peak Plasma Concentration [Cmax,ss] (For Multiple Dose)
ng/mLSaroglitazar Magnesium 4 mg
Peak Plasma Concentration [Cmax,ss] (For Multiple Dose)137.210 ± 57.770
SecondaryTime to Reach Peak Plasma Concentration [Tmax,ss] (For Multiple Dose)

Pharmacokinetics of Saroglitazar following last dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Reported as:
Mean · hour
Time to Reach Peak Plasma Concentration [Tmax,ss] (For Multiple Dose)
hourSaroglitazar Magnesium 4 mg
Time to Reach Peak Plasma Concentration [Tmax,ss] (For Multiple Dose)1.667 ± 0.866
SecondaryArea Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval (AUCtau) After Last Dose (For Multiple Dose)

Pharmacokinetics of Saroglitazar following last dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Reported as:
Mean · ng*hr/mL
Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval (AUCtau) After Last Dose (For Multiple Dose)
ng*hr/mLSaroglitazar Magnesium 4 mg
Area Under Plasma Concentration vs. Time Curve in a 24 h Dosing Interval (AUCtau) After Last Dose (For Multiple Dose)454.916 ± 162.275
SecondaryElimination Rate Constant [Kel,ss] (For Multiple Dose)

Pharmacokinetics of Saroglitazar following last dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (Visit 8)
Reported as:
Mean · 1/hr
Elimination Rate Constant [Kel,ss] (For Multiple Dose)
1/hrSaroglitazar Magnesium 4 mg
Elimination Rate Constant [Kel,ss] (For Multiple Dose)0.147 ± 0.047
SecondaryElimination Half-life [Thalf,ss] (For Multiple Dose)

Pharmacokinetics of Saroglitazar following last dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Reported as:
Mean · hour
Elimination Half-life [Thalf,ss] (For Multiple Dose)
hourSaroglitazar Magnesium 4 mg
Elimination Half-life [Thalf,ss] (For Multiple Dose)5.196 ± 1.790
SecondaryApparent Volume of Distribution [Vd/F,ss] (For Multiple Dose)

Pharmacokinetics of Saroglitazar following last dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Reported as:
Mean · L
Apparent Volume of Distribution [Vd/F,ss] (For Multiple Dose)
LSaroglitazar Magnesium 4 mg
Apparent Volume of Distribution [Vd/F,ss] (For Multiple Dose)66.047 ± 28.325
SecondaryApparent Clearance [CL/F,ss] (For Multiple Dose)

Pharmacokinetics of Saroglitazar following last dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Reported as:
Mean · L/hr
Apparent Clearance [CL/F,ss] (For Multiple Dose)
L/hrSaroglitazar Magnesium 4 mg
Apparent Clearance [CL/F,ss] (For Multiple Dose)8.883 ± 2.444
SecondaryMinimal or Trough Plasma Concentration [Cmin] (For Multiple Dose)

Pharmacokinetics of Saroglitazar following last dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Reported as:
Mean · ng/mL
Minimal or Trough Plasma Concentration [Cmin] (For Multiple Dose)
ng/mLSaroglitazar Magnesium 4 mg
Minimal or Trough Plasma Concentration [Cmin] (For Multiple Dose)1.053 ± 0.825
SecondaryFluctuation Index (For Multiple Dose)

Pharmacokinetics of Saroglitazar following the last dose. It is calculated as (Cmax - Cmin) / Cavg. The value has been multiplied by 100, hence has been expressed in percentage unit; where Cmax is the Maximum measured plasma concentration at steady state, Cmin is Minimal or trough plasma concentration at steady state, and Cavg is Average concentration = AUCtau,ss /tau.

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Reported as:
Mean · percentage
Fluctuation Index (For Multiple Dose)
percentageSaroglitazar Magnesium 4 mg
Fluctuation Index (For Multiple Dose)676.702 ± 240.892
SecondaryAccumulation Index Calculated as a Ratio of AUCtau (Last Dose)/AUCtau (First Dose) (For Multiple Dose)

Pharmacokinetics of Saroglitazar following last dose

Time frame:
PK sampling timepoints: pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Last dose (visit 8)
Reported as:
Mean · ratio
Accumulation Index Calculated as a Ratio of AUCtau (Last Dose)/AUCtau (First Dose) (For Multiple Dose)
ratioSaroglitazar Magnesium 4 mg
Accumulation Index Calculated as a Ratio of AUCtau (Last Dose)/AUCtau (First Dose) (For Multiple Dose)1.113 ± 0.264

Adverse events

Collected over 30 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saroglitazar Magnesium 4 mg0/30 (0%)0/30 (0%)19/30 (63.3%)
Placebo0/30 (0%)0/30 (0%)22/30 (73.3%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventSaroglitazar Magnesium 4 mgPlacebo
HeadacheNervous system disorders5/301/30
General disorders and administration site conditionsGeneral disorders3/304/30
Abdominal painGastrointestinal disorders3/302/30
GastritisGastrointestinal disorders3/300/30
NauseaGastrointestinal disorders3/303/30
VomitingGastrointestinal disorders3/301/30
DiarrheaGastrointestinal disorders1/303/30
Urinary tract infectionInfections and infestations3/301/30
AnxietyPsychiatric disorders1/303/30
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders2/303/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Saroglitazar Magnesium 4 mgPlaceboTotal
Mean28.5 ± 7.1627.2 ± 5.7927.9 ± 6.49
Sex: Female, Male
Sex: Female, Male(Participants)Saroglitazar Magnesium 4 mgPlaceboTotal
Female303060
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Saroglitazar Magnesium 4 mgPlaceboTotal
Hispanic or Latino182139
Not Hispanic or Latino12921
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Saroglitazar Magnesium 4 mgPlaceboTotal
White201535
Asian112
Mestizo91322
Other011
BMI
BMI(kg/m^2)Saroglitazar Magnesium 4 mgPlaceboTotal
Mean40.14 ± 7.63637.81 ± 6.98138.97 ± 7.348
08

Study locations

19 sites
  • Zydus US005
    Chandler, Arizona 85224, United States
  • Zydus US004
    Panorama City, California 91402, United States
  • Zydus US002
    San Francisco, California 94143, United States
  • Zydus US008
    Aurora, Colorado 80045, United States
  • Zydus US010
    Miami, Florida 33125, United States
  • Zydus US001
    Indianapolis, Indiana 46202, United States
  • Zydus US011
    Morehead City, North Carolina 28557, United States
  • Zydus US003
    Marion, Ohio 43302, United States
  • Zydus US015
    Hershey, Pennsylvania 17033, United States
  • Zydus US014
    Philadelphia, Pennsylvania 19104, United States
  • Zydus US013
    Austin, Texas 78745, United States
  • Zydus US007
    San Antonio, Texas 78215, United States
  • Zydus US009
    San Antonio, Texas 78229, United States
  • Zydus MX006
    Guadalajara, Jalisco 44130, Mexico
  • Zydus MX001
    Monterrey, Nuevo León 64460, Mexico
  • Zydus MX002
    Monterrey, Nuevo León 64460, Mexico
  • Zydus MX005
    Culiacán, Sinaloa 80230, Mexico
  • Zydus MX004
    Mérida, Yucatán 97070, Mexico
  • Zydus MX003
    Mexico City, 06100, Mexico
09

References and documents

Publications

  • Kelley CE, Brown AJ, Diehl AM, Setji TL. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol. 2014 Oct 21;20(39):14172-84. doi: 10.3748/wjg.v20.i39.14172. PubMed 25339805 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Oct 2024, 68 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2018
First posted
Aug 6, 2018
StartActual
Feb 12, 2019
Primary completionActual
Oct 28, 2024
CompletionActual
Oct 28, 2024
Results first posted
Dec 18, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03617263
Responsible party
Sponsor
First posted
Aug 6, 2018
Start date
Feb 12, 2019
Primary completion
Oct 28, 2024
Completion
Oct 28, 2024
Results posted
Dec 18, 2025
Last update
Dec 18, 2025

Study contacts

Deven Parmar, MD
study director · Zydus Therapeutics Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saroglitazar

Start the discussion